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Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implan-
tation. All patients with HM2 implanted in our institution were included. All clin-
ical and ultrasound data were restrospectively collected. Each patient was
regurlarly followed until the end of data collection in April 2015. From January
2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe
myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in
bridge to cardiac transplantation (72%), were included. Before implantation, 20
had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained
ventricular tachycardia (VT). The overall mortality rate was 60% with a mean
follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after
implantation, with a median delay of 9±8 days. Early AS often occured in heavier
patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2,
p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term
treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy eti-
ology, the indication of assistance or the emergy of implantation were not associ-
ated with early AS, as an AS occuring just prior LVAD implantation (11 patients).
No AS occured under a Betablocker therapy. VT ablation was performed in 10
patients under assistance. The substrate of VT was not related to HM2 cannula.
Arrhythmic storm are frequent (28%) in the early period of HM II implantation. 
The author hereby declares no conflict of interest
0377
Can we predict right heart failure after implantable left ventricular
assist device?
Marylou Para*, Clément Delmas, L. Bocquillon, Bertrand Marcheix,
Jérome Roncalli, Michel Galinier, Camille Dambrin 
CHU Toulouse, Rangueil, Toulouse, France
*Corresponding author: para.marylou@wanadoo.fr (Marylou Para)
Objectives The right ventricular failure (RVF) is a severe complication
after implantation of a left ventricular assist device (LVAD), difficult to pre-
dict and treat. The purpose of this study was to identify risk factors of RVF
after mechanical circulatory support.
Methods This is a single-center prospective cohort of patients with long-
term electrical intracorporeal continuous flow LVAD type HeartMate II
between January 2008 and September 2014. We searched predictors of RVF,
defined by a need of inhaled nitric oxide ≥48 hours and / or intravenous ino-
tropes ≥14 days.
Results 42 devices were implanted in 36 men and 6 women with a mean
age of 57.3 years, for 30 ischemic and 12 primitive cardiomyopathies, 10
cases in “Destination Therapy” and 32 cases in “Bridge-to-Transplantation.”
The 30-day mortality was 6 patients, 1-year survival of 84%, the mean last of
intubation was 7 days and ICU stay of 16.3 days. There were 16 cases of RVF
(38.1%). The significantly associated factors (p<0.05) were: subaortic time
velocity integral (10.5 versus 13.8cm), grade (1.4 versus 0.3) and maximal
speed of the triscuspid regurgitation (3 versus 3.5 m/s), fractional shortening
(27 versus 36.4%) and surface of the right ventricle (33.4 versus 22cm2), cap-
illary (26.3 versus 18.3mmHg) and mean pulmonary arterial pressures (38.7
versus 27.2mmHg), transpulmonary gradient (14 versus 8.5mmHg), pulmo-
nary arterial resistances (3.7 versus 2.7 UW), right ventricular (26 versus
8.1mmHg) and atrial pressures (11 versus 5.5mmHg), bilirubin (28.3 versus
15.7μmol/l), INTERMACS score (3.3 versus 4.4), non-ischemic etiologies (50
versus 85%) and preoperative inotropic drugs (56 versus 15%).
Conclusion RVF remains a major complication in implantable LVAD.
According to the literature, preoperative pulmonary hypertension, right sys-
tolic dysfunction and cavitary dilation seem to favor its appearance.
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Objectives Hemorrhagic complications are a main concern after mechan-
ical circulatory support, alternative to heart transplantation, and often involve
multiple transfusions and re-interventions at the initial phase. The Recombi-
nant activated factor VII (NovoSeven®), expensive drug with proven blood
savings in some coagulopathies, can help control mediastinal bleeding but
runs the risk of pump thrombosis.
Methods This is a single-center prospective cohort of patients wtih long-
term electrical intracorporeal continuous flow left ventricular assist device
(LVAD) type HeartMate II, between January 2008 and September 2014. We
studied the post-operative use of blood products and their derivatives, espe-
cially NovoSeven®, and its consequences on the level of bleeding and throm-
boembolism. 
Results 42 devices were implanted in 36 men and 6 women with a mean
age of 57.3 years, for 30 ischemic and 12 primitive cardiomyopathies, 10
cases in “Destination Therapy” and 32 in “Bridge-to-Transplantation”. The
30-day mortality was 6 patients, 1-year survival of 84%, the average intuba-
tion period of 7 days and ICU stay of 16.3 days. The average volume of tho-
racic drainage was 3036mL. The average transfusion per patient was 10.4 red
blood cells, 7.1 fresh frozen plasma, 16.3 platelet units, 2.4g of fibrinogen
(Clottafact®), 1162 IU of clotting factors (Octaplex®) and 2.9g of
NovoSeven®. 17 patients (40.5%) received NovoSeven® (ranging from 4 to
15mg) including 8 during the procedure because of precarious hemostasis.
Only 6 patients (14.3%) required reoperation for tamponade within J0 and J9,
including 4 who had NovoSeven® prior. 6 patients (14.3%) had an intracardiac
thrombus remote, 3 had received NovoSeven®.
Conclusion An aggressive transfusion policy after LVAD can greatly limit
the rate of surgical re-openings for bleeding, recognized as a risk factor for
wound infection, without causing major thrombotic event.
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Background In patients undergoing transcatheter aortic valve implantation
(TAVI), measurement of pulmonary pressure helps to stratify clinical risk.
However, data may lead to misclassification and role of pulmonary vascular
resistance (PVR) has never been investigated.
Methods and results One hundred and seventy one consecutive patients
with significant symptomatic aortic stenosis who prospectively were sched-
uled for TAVI, underwent preoperative right-sided heart catheterization. Of
these, 99 (57.9%) had pulmonary hypertension and 40 experienced cardiac
events during a 1-year follow-up (readmission for heart failure in 16 patients,
all cause death in 24). Patients who had events exhibited a higher both peak
systolic PAP (46.9±12.1 versus 40.8±12.0mmHg; p=0.026) and transpulmo-
nary pressure gradient (12.6±4.5 versus 10.1±3.7mmHg; p=0.011), as well as
increased PVR (2.7±1.0 vs. 2.0±0.8 WU, p=0.002). Systolic PAP>40mmHg
and PVR>2.05 WU were selected by receiver operating curve for predicting
cardiac events. By multivariate Cox regression analysis, independent predic-
tors of cardiac events were: body mass index (p=0.005), mitral regurgitation
(p=0.018), and a spectrum of systolic PAP>40mmHg with PVR>2.05 WU
(2.6 [1.39-4.89], p=0.003).
Conclusion Right heart catheterization could be useful to identify a high-
risk subset of aortic stenosis patients candidate for TAVI and help for clinical
decision. 
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